Linda Boniface Oyama

Linda Boniface Oyama

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Linda Boniface Oyama has a total of 113 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Influence of the Nature of the Cationic Residues on the Activity of the Antimicrobial Peptides of the Lynronne Family

    by Alexis Reinbold, Maxime Gâchon, Jean‐François Cavalier, Laure Genet, Sophie Guillier, Mathilde Lescat, Muriel Serradeil‐Albalat, Linda B. Oyama, Cendrine Nicoletti, Sharon A. Huws, et al.

    Most antimicrobial peptides (AMPs) are cationic, with positively charged amino acid residues (i.e., arginine, lysine, and/or histidine) being responsible for their selective interaction with bacteria. In the present study, we investigated the influence of the nature of cationic residues taking the Lynronnes peptides as models. Derivatives were designed and synthetized with substitutions of the type of cationic residues present. All derivatives and parental peptides were studied in terms of secondary structure, antimicrobial activity, anti‐biofilm activity, mechanism of action, and in vitro toxicity. All‐His peptides were found inactive, whereas all‐Lys variants showed the highest potency against Gram‐negative strains, particularly against E. coli . All‐Arg analogues were more active against Gram‐positive strains with enhanced stability under salt or serum conditions but were also more hemolytic. Mechanistic studies revealed that the peptides act by membrane permeabilization. Finally, Lynronne‐3 and its all‐Lys derivative proved the most effective in both the prevention and eradication of biofilms. These findings confirm that the type of cationic residue present in AMPs affects their activity, toxicity, and sensitivity to host factors, with different effects depending on the rest of the amino acid sequence, Lys‐substitution emerging as a promising strategy in the case of Lynronnes for targeting E. coli .

  • Open Access

    The bovine milk microbiome as a One Health interface for antimicrobial resistance, food safety and nutrition

    by Mustasim Famous, Karen Siu-Ting, Catherine Hambly, Linda B Oyama

  • Open Access

    From sequence space to ecological function: microbiome-derived antimicrobial peptides as community effectors and therapeutic leads

    by Linda Boniface Oyama

    Antimicrobial peptide research has long centred on host defence molecules, yet microbiomes themselves encode a diverse and increasingly important repertoire of peptide-based antimicrobials. These microbiome-derived antimicrobial peptides include bacteriocins, ribosomally synthesised and post-translationally modified peptides, cryptic short open reading frame-encoded peptides, embedded antimicrobial regions within larger proteins, and selected peptide antibiotics recovered from human, animal, plant and environmental microbiomes. Recent advances in genome mining, metagenomics, and machine learning have greatly expanded the scale of discovery, moving the field from a handful of landmark exemplars to large candidate catalogues spanning the global microbiome. In the clearest cases, these molecules are not only anti-infective leads but ecological effectors: they mediate microbial competition, enforce colonisation resistance, and influence community structure within densely occupied niches. The present review synthesises the field across discovery classes, microbiome sources, ecological roles, and translational bottlenecks, emphasizing a central limitation of the field: candidate catalogues are expanding at extraordinary scale, while evidence for native expression, producer assignment, ecological function, and in vivo relevance remains limited for the vast majority of predicted molecules. Progress will depend on workflows that connect sequence level prediction to biological context through expression support, producer assignment, community level validation, and perturbation-based approaches that distinguish ecological association from causal function. Microbiome-derived antimicrobial peptides are best understood not only as promising therapeutic leads, but also as molecular mediators of microbial social life whose ecological origins are central to their interpretation and future application.


  • Open Access

    Antimicrobial peptides for tuberculosis in a post-antibiotic era: from in vitro promise to therapeutic potential

    by Gama Dominic, Yasmin Neves Vieira Sabino, Mustasim Famous, Omololu Ebenezer Fagunwa, Rachel M. Wheatley, Ralf Bauer, Suzanne Hingley-Wilson, Linda B. Oyama

    Tuberculosis remains the leading cause of death from a single infectious pathogen, driven by prolonged treatment regimens and escalating drug resistance. Antimicrobial peptides represent a promising alternative therapeutic class with diverse mechanisms and limited resistance emergence. This review distinguishes anti-mycobacterial from anti- Mycobacterium tuberculosis peptides and systematically analyses 22 candidates curated in the APD6 alongside additional literature reports. We evaluate their structural and physicochemical determinants of activity, mechanistic evidence in vitro and in vivo, and synergy with conventional agents. Finally, we discuss rational design strategies, machine learning-guided optimisation, and translational barriers that must be overcome to realise peptide-based tuberculosis therapeutics.

  • Open Access

    From the lens of early-career researchers: bridging science, technology, arts, and humanities to tackle antimicrobial resistance

    by Nikhil Bhalla, Mojgan Rabiey, Prachi Bendale, Katie Lawther, Janice Spencer, Alberto Longo, Lucky Lucky, Vishal Chaudhary, Paul McCormack, Saikat Jana, et al.

    Antimicrobial resistance (AMR) is a silent pandemic that presents a global challenge, urging researchers to develop innovative and transdisciplinary solutions. Our initiative aims to promote collaboration across science, engineering, economics, social sciences, and the arts to address the complex dimensions of AMR. We highlight the unique role of early-career researchers (ECRs) in advancing such cross-cutting approaches and conclude that empowering ECRs through equitable support and recognition is essential to sustaining innovation and mobilising communities against AMR.


  • Anti-biofilm and anti-infection activities of Lynronne-1 against major bovine mastitis pathogens

    by Ana Júlia Silva Moreira, Katialaine Corrêa Araújo Domingues, Jennifer McClure, Karine Dalla Vecchia Camargo, Nicole Aulik, Linda Boniface Oyama, Sharon A. Huws, Hilario C. Mantovani


  • Open Access

    Unravelling AMR dynamics in the rumenofaecobiome: Insights, challenges and implications for One Health

    by Ziming Wu, Mustasim Famous, Theano Stoikidou, Freya E.S. Bowden, Gama Dominic, Sharon A. Huws, Fernanda Godoy-Santos, Linda B. Oyama


  • Open Access

    Microbiome-derived antimicrobial peptides show therapeutic activity against the critically important priority pathogen, Acinetobacter baumannii

    by P. J. Alexander, L. B. Oyama, H. Olleik, F. Godoy Santos, S. O’bRien, A. Cookson, S. A. Cochrane, B. F. Gilmore, M. Maresca, S. A. Huws

    Acinetobacter baumannii is designated by the World Health Organisation as a critical priority pathogen. Previously we discovered antimicrobial peptides (AMPs), namely Lynronne-1, -2 and -3, with efficacy against bacterial pathogens, such as Staphylococcus aureus and Pseudomonas aeruginosa. Here we assessed Lynronne-1, -2 and -3 structure by circular dichroism and efficacy against clinical strains of A. baumannii. All Lynronne AMPs demonstrated alpha-helical secondary structures and had antimicrobial activity towards all tested strains of A. baumannii (Minimum Inhibitory Concentrations 2–128 μg/ml), whilst also having anti-biofilm activity. Lynronne-2 and -3 demonstrated additive effects with amoxicillin and erythromycin, and synergy with gentamicin. The AMPs demonstrated little toxicity towards mammalian cell lines or Galleria mellonella. Fluorescence-based assay data demonstrated that Lynronne-1 and -3 had higher membrane-destabilising action against A. baumannii in comparison with Lynronne-2, which was corroborated by transcriptomic analysis. For the first time, we demonstrate the therapeutic activity of Lynronne AMPs against A. baumannii.


  • Open Access

    Lynronne antimicrobial peptides with terminal D amino acid enantiomers synergize with bedaquiline against Mycobacterium tuberculosis

    by Suzie Hingley-Wilson, Ye Xu, Linda Oyama, Winifred Akwani, Rosalyn Casey, Sharon Huws, Johnjoe McFadden

    Tuberculosis (TB) treatment is challenging due to prolonged chemotherapy and rising multidrug resistance. Here, we investigated the antimicrobial properties of the antimicrobial peptides (AMPs) lynronne (LYN)-1, -2 and -3, both in their natural form or with terminal D-enantiomers, alongside their synergistic effects with common TB drugs. Notably, D-enantiomer replacement improves LYNs’ stability and activity. Moreover, lynronne-1D (LYN1D) and lynronne-3D (LYN3D) is synergistic with bedaquiline (BDQ), significantly reducing the bactericidal concentrations of LYN1D, LYN3D and BDQ. Transcriptome studies demonstrated that this synergy is associated with perturbation of multiple pathways, including negative transcriptional regulators, lipid transporters, arabinogalactan biosynthesis, and the oxidative phosphorylation pathway. Furthermore, cellular morphology changes and ATP reduction suggested a synergistic model where the combination of LYNDs with BDQ simultaneously targets cell membrane lipids and energy production, resulting in the eradication of Mycobacterium tuberculosis. This synergistic combination of BDQ with D-enantiomers AMPs offers a novel TB treatment strategy, and a model for developing synergistic drug combinations to tackle other infectious diseases.

  • Open Access

    Microbiome-derived antimicrobial peptides show therapeutic activity against the critically important priority pathogen, Acinetobacter baumannii

    by Sharon Huws, Peter Alexander, Linda Oyama, Hamza Olleik, Fernanda Santos, Seamus O'Brien, Alan Cookson, Stephen Cochrane, Brendan Gilmore, Marc Maresca

    Acinetobacter baumannii is recognised as a priority 1 critically important pathogen by the World Health Organisation. The cow rumen has previously yielded antimicrobial peptides namely Lynronne-1, -2 and -3 with high efficacy against bacterial pathogens, such as Staphylococcus aureus and Pseudomonas aeruginosa. In this study we assessed the structure by circular dichroism and efficacy of Lynronne-1, -2 and -3 against clinical strains of A. baumannii. Lynronne-1, -2 and -3 demonstrated alpha-helical secondary structures and had antimicrobial activity towards all tested strains of A. baumannii (Minimum Inhibitory Concentrations 2-128 μg/ml). Lynronne-2 and -3 also demonstrated additive effects with amoxicillin and erythromycin, and synergy with gentamicin. The AMPs demonstrated little toxicity towards mammalian cell lines or Galleria mellonella. Antibiofilm activity was observed with all three AMPs. Lynronne-1 and -3 demonstrated higher membrane-destabilising action against A. baumannii in comparison with Lynronne-2 in a fluorescence-based assay. This was corroborated by transcriptomic analysis which highlighted several gene expression changes related to cell wall synthesis following addition of the AMPs. For the first time we demonstrate the therapeutic activity of Lynronne AMPs against A. baumannii.